title: Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
abstract: The idiopathic inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis are associated with increased risk of hematologic malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) could be a curative strategy in this setting, but has been thought to be associated with increased nonrelapse mortality (NRM). We conducted a national French retrospective analysis of patients with IBD who underwent allogeneic HSCT for hematologic malignancies and were matched with 3 controls according to recipient, donor, and transplant characteristics. Between 2004 and 2015, 18 patients with IBD underwent allogeneic HSCT. With a median follow-up of 33 months for the patients with IBD and 57 months for controls, the cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 39% for the patients with IBD and 40% for controls (hazard ratio [HR], 1.10; P = .82). The cumulative incidence of chronic GVHD at 48 months was 52% for the patients with IBD and 43% for controls (HR, 0.92; P = .89). Nonrelapse mortality at 48 months was 19% for the patients with IBD and 11% for controls (HR, 4.93; P = .067). Overall survival at 48 months was 59% for the patients with IBD and 60% for matched controls (HR, 1.35; P = .56). In conclusion, IBD should not be considered a contraindication for transplantation, and its impact on comorbidity indexes should be reduced.
authors.affiliation: APHP, Hematology Transplantation, St. Louis Hospital, Paris, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Rabian
authors.affiliation: APHP, Center for Clinical Epidemiology, Hôtel-Dieu Hospital, Paris, France.
authors.forename: Raphael
authors.initials: R
authors.lastname: Porcher
authors.affiliation: APHP, Hematology Transplantation, St. Louis Hospital, Paris, France.
authors.forename: Flore
authors.initials: F
authors.lastname: Sicre de Fontbrune
authors.affiliation: CHRU de Strasbourg, Hematology, Hopital de Hautepierre, Strasbourg, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Lioure
authors.affiliation: CHRU de Strasbourg, Hematology, Hopital de Hautepierre, Strasbourg, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Laplace
authors.affiliation: APHP, Hematology, Pitié Salpêtrière Hospital, Paris, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Nguyen
authors.affiliation: Hematology, CHU Bordeaux, Hopital Haut-Leveque, Pessac, France.
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizi
authors.affiliation: Hematology, CHU Bordeaux, Hopital Haut-Leveque, Pessac, France.
authors.forename: Stephane
authors.initials: S
authors.lastname: Vigouroux
authors.affiliation: Department of Oncology Hematology and Cell Therapy, Poitiers University Hospital, Poitiers, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Tomowiak
authors.affiliation: Department of Oncology Hematology and Cell Therapy, Poitiers University Hospital, Poitiers, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Maillard
authors.affiliation: APHP, Hematology Adult Unit, Necker Hospital, Paris, France; Paris Descartes University, Paris, France.
authors.forename: Felipe
authors.initials: F
authors.lastname: Suarez
authors.affiliation: Hematology, CHU Montpellier, St. Eloi Hospital, Montpelier, France.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Delage
authors.affiliation: APHP, Hematology Transplantation, St. Louis Hospital, Paris, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Peffault de Latour
authors.affiliation: APHP, Hematology Transplantation, St. Louis Hospital, Paris, France; Inserm UMR 1160, Paris, France; University Paris 7, Paris, France. Electronic address: gerard.socie@aphp.fr.
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006086:Graft vs Host Disease / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
keywords: Acute graft-versus-host disease; Allogeneic hematopoietic stem cell transplantation; Chronic graft-versus-host disease; Comorbidity index; Hematologic malignancies; Inflammatory bowel disease